BiotechTube

KK8123

Phase 1/2Recruiting
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

X-linked Hypophosphatemia

Conditions

X-linked Hypophosphatemia

Trial Timeline

Oct 9, 2024 → May 10, 2028

NCT ID
NCT06525636

About KK8123

KK8123 is a phase 1/2 stage product being developed by Kyowa Kirin for X-linked Hypophosphatemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06525636. Target conditions include X-linked Hypophosphatemia.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT06525636Phase 1/2Recruiting

Competing Products

20 competing products in X-linked Hypophosphatemia

See all competitors
ProductCompanyStageHype Score
VK0214Viking TherapeuticsPhase 1
28
Methylprednisolone + Prednisolone + SirolimusAstellas PharmaPhase 1/2
41
BurosumabKyowa KirinPhase 1/2
41
BurosumabKyowa KirinPre-clinical
23
BurosumabKyowa KirinPre-clinical
23
BurosumabKyowa KirinPhase 2
52
KRN23Kyowa KirinPhase 1/2
41
KRN23Kyowa KirinPhase 3
77
burosumab + Oral Phosphate Supplement + active vitamin DKyowa KirinPhase 3
77
burosumabKyowa KirinPhase 3
77
KRN23Kyowa KirinApproved
85
burosumabKyowa KirinPhase 2
52
BurosumabKyowa KirinPhase 3
77
KRN23Kyowa KirinPhase 1/2
41
Placebo + KRN23Kyowa KirinPhase 1
33
BurosumabKyowa KirinPhase 3
77
burosumabKyowa KirinPhase 3
77
KRN23Kyowa KirinPhase 2
52
KRN23Kyowa KirinPhase 1
33
KRN23Kyowa KirinApproved
85

Other Products from Kyowa Kirin

KRN23Approved
85
Istradefylline PillApproved
85
MogamulizumabApproved
85
KRN23Approved
85
KHK4827-Active + KHK4827-PlaceboApproved
85